BRENDA CUPP: Open Payments
NPI 1366530628 · JOPLIN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$662 in 36 payments from 13 companies in 2025. Trend: 2023 $428 · 2024 $3,263 · 2025 $662
Food & beverage: $662
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $142 |
| Novartis Pharmaceuticals Corporation | 6 | $91 |
| E.R. Squibb & Sons, L.L.C. | 4 | $72 |
| Amgen Inc. | 4 | $61 |
| Abbott Laboratories | 2 | $59 |
| Alnylam Pharmaceuticals Inc. | 3 | $54 |
| Novo Nordisk Inc | 3 | $48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $34 |
| Boston Scientific Corporation | 1 | $27 |
| Organogenesis Inc. | 1 | $23 |
Products named: LEQVIO, LOKELMA, REPATHA, ELIQUIS, AMVUTTRA, Wegovy, JARDIANCE, CAMZYOS.
Industry payments across MO — which companies pay providers there.
